Abstract: We know that creatures like us have two separate systems for processing information, the genome and the brain. We know that the genome is digital, and we can accurately transcribe our genomes onto digital machines. We cannot transcribe our brains, and the processing of information in our brains is still a great mystery. I will be talking about real brains and real people, asking a question that will have practical consequences when we are able to answer it. I am not able to answer it now. All I can do is to examine the evidence and explain why I consider it probable that the answer will be that brains are analog.

Prof Freeman Dyson | “Are Brains Analogue or Digital?” | 19th May 2014 — Dublin Institute for Advanced Studies, Statutory Public Lecture of the School of Theoretical Physics, in association with the UCD School of Physics.

*****
Dublin Institute for Advanced Studies: http://www.dias.ie
UCD School of Physics: http://www.ucd.ie/physics
UCD: http://www.ucd.ie
UCD Twitter: http://www.twitter.com/ucddublin
UCD Instagram: http://www.instagram.com/ucddublin
UCD Facebook: http://www.facebook.com/ucdlife
UCD Google+: https://plus.google.com/+universitycollegedublin

A fascinating new study from scientists at UC Berkeley has homed in on exactly which phase of sleep seems to best keep anxiety levels in check. The research both affirms a causal association between sleep and anxiety, and suggests sleep deprivation lowers activity in the prefrontal cortex, an area of the brain that helps regulate our emotions.

For well over a century scientists have observed a correlation between sleep disruption and mood disorders such as anxiety and depression. Only in the last few years have clear neural mechanisms been discovered helping us understand exactly what our brains are doing when we are asleep, and how physiologically disruptive sleep deprivation can be.

A new study from UC Berkeley has focused more specifically on how sleep can modulate a person’s anxiety levels. Using a number of experimental measures, including polysomnography and functional MRI, the research first found that just one night of sleep deprivation resulted in 50 percent of the study subjects reporting anxiety levels the next day equal to those detected in subjects with clinically diagnosed anxiety disorders.

In a surprise to many researchers around the world, Chinese authorities recently approved a novel drug claimed to improve cognitive function in patients with Alzheimer’s disease. The drug, derived from a marine algae, is the first new Alzheimer’s drug to reach the market anywhere in the world in almost 20 years, and is suggested to reduce neuroinflammation by modulating a person’s gut microbiome.

GV-971, or sodium oligomannate, is derived from a common form of seaweed called brown algae. For several years the compound has been under investigation in China as a treatment to slow, or even reverse, cognitive decline associated with mild to moderate cases of Alzheimer’s disease.

The latest announcement from China’s National Medical Products Administration (NMPA) has granted the drug “conditional approval”, meaning it is to be fast-tracked to market based on positive early Phase 3 trial results. The “conditional approval” requires ongoing studies to verify efficacy and safety, however, it can now move to open market sales in China within the next month or two.